Loading...
01/10 20:13
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects a mixed to negative sentiment. Despite some positive developments like sales growth in North America and Europe, the overall financial performance is weak with declining revenue, gross profit, and margins. The uncertainty around FDA approval and the need for a post-market study pose significant risks. Additionally, the issuance of new shares and reliance on loans indicate financial strain. The Q&A session highlights management's inability to provide clear guidance, further contributing to negative sentiment. These factors suggest a likely negative stock price movement in the short term.
Revenue $725,000 (down from $743,000), a decrease of approximately 2.4% year-over-year, driven primarily by increased sales in North America and Europe, offset by a decline in sales in Asia.
Gross Profit $218,000 (down from $269,000), a decrease of approximately 19% year-over-year, with a gross margin of 30% compared to 36% last year, attributed to the low revenue base.
Total Operating Expenses $3.88 million (down from $3.92 million), a decrease of approximately 1% year-over-year, reflecting ongoing efforts to manage costs.
Net Loss $3.59 million or $0.06 per share (compared to a net loss of $3.61 million or $0.08 per share), a slight improvement year-over-year.
Cash and Cash Equivalents Approximately $6.0 million as of March 31, 2025, and approximately $6.2 million as of May 27, 2025, including a $2 million unsecured bridge loan from Epoch.
Net Proceeds from Share Sales $2.65 million raised from the sales of 2,124,429 ordinary shares between January 13, 2025, and May 27, 2025.
ProSense System: The ProSense system is expected to receive FDA marketing authorization for treating early-stage low-risk breast cancer in women aged 70 and over, with commercial sales planned to commence upon approval.
Market Expansion: The company is experiencing growth in ProSense system and disposable probe sales in North America and Europe, with a demographic of approximately 46,000 patients annually in the US.
Operational Efficiency: The company reported a gross profit of $218,000 for Q1 2025, with a gross margin of 30%, indicating a focus on building commercial infrastructure.
Strategic Shift: IceCure Medical is preparing a post-market study plan as requested by the FDA, which is seen as a positive signal for future marketing authorization.
FDA Marketing Authorization Risks: The company is awaiting the FDA's decision on marketing authorization for ProSense, which is subject to the approval of a post-market study plan. Delays or unfavorable outcomes could impact commercial sales.
Regulatory Challenges: The requirement for a post-market study by the FDA introduces additional regulatory hurdles that could affect the timeline for commercial sales and reimbursement.
Sales Fluctuation Risks: Revenue and gross profit are expected to fluctuate quarter-to-quarter due to the low revenue base and reliance on FDA marketing authorization.
Competitive Pressures: The company faces competition in the minimally invasive treatment market for breast cancer, which could impact market share and sales.
Economic Factors: The overall economic environment and healthcare spending could influence the adoption of ProSense and reimbursement rates.
Supply Chain Challenges: Potential supply chain issues could affect the availability of ProSense systems and disposable probes, impacting sales.
FDA Meeting: IceCure Medical had a positive high-level meeting with the FDA regarding the marketing authorization request for ProSense in treating early-stage low-risk breast cancer.
Post-Market Study Plan: The FDA requested a post-market study plan after marketing authorization, which IceCure has submitted for review.
Commercial Sales: IceCure plans to commence commercial sales of ProSense in parallel with the post-market study.
Reimbursement Potential: The company anticipates access to reimbursement under the CPT III code, covering $3,800 for treatment facility costs.
Interest from Surgeons: High interest in ProSense was noted at the American Society of Breast Surgeons 2025 Annual Meeting, with many surgeons inquiring about participation in the post-market study.
International Expansion: IceCure is looking ahead to regulatory filings and potential approvals in Japan and Israel.
Support from Shareholder: Epoch Partner Investor Limited provided a $2 million unsecured loan to support the company as it awaits FDA decisions.
Revenue Expectations: Revenue for Q1 2025 was $725,000, with expectations of fluctuations until FDA marketing authorization is received.
Gross Margin: Gross margin for Q1 2025 was 30%, down from 36% in Q1 2024.
Operating Expenses: Total operating expenses for Q1 2025 were $3.88 million, slightly down from $3.92 million in Q1 2024.
Net Loss: Net loss for Q1 2025 was $3.59 million, or $0.06 per share.
Cash Position: As of May 27, 2025, cash and cash equivalents were approximately $6.2 million, including the $2 million bridge loan.
Unsecured Loan: Epoch Partner Investor Limited provided a $2 million unsecured loan at an interest rate matching US treasury bills.
Equity Transaction Participation: The loan will be prepaid prior to its one-year term upon Epoch's participation in an equity transaction.
Share Sales: The company raised $2.65 million in net proceeds from the sales of 2,124,429 ordinary shares under its at-the-market offering facility.
The company's financial performance shows declining revenue, gross profit, and margins, indicating challenges in maintaining profitability. Despite the optimism around FDA approval and market potential, the lack of a concrete timeline for regulatory approvals and the unclear management responses in the Q&A create uncertainty. The ongoing net losses and limited cash position add to financial strain. These factors, combined with supply chain and sales variability, suggest a negative market reaction, likely in the -2% to -8% range, especially given the lack of market cap information for a more precise prediction.
The earnings call reveals several concerns: declining revenue and gross margin, increased net loss, and dependency on FDA approval for U.S. market growth. The Q&A highlighted uncertainties around the post-market study budget and lack of specific sales projections for Europe and Japan. While there is interest in ProSense and potential reimbursement, the financial metrics and market adoption risks overshadow these positives, suggesting a negative sentiment.
The earnings call presents several challenges: ongoing financial losses, dependency on FDA approval for revenue growth, and competitive pressures. Despite some positive developments like increased sales in North America and Europe, the decline in Asia and supply chain issues are concerning. The Q&A revealed uncertainties in regulatory timelines and management's unclear responses. The unsecured loan and share sales indicate financial strain. These factors, coupled with the lack of immediate revenue change expectation, suggest a negative sentiment, likely leading to a stock price decline in the next two weeks.
The earnings call reflects a mixed to negative sentiment. Despite some positive developments like sales growth in North America and Europe, the overall financial performance is weak with declining revenue, gross profit, and margins. The uncertainty around FDA approval and the need for a post-market study pose significant risks. Additionally, the issuance of new shares and reliance on loans indicate financial strain. The Q&A session highlights management's inability to provide clear guidance, further contributing to negative sentiment. These factors suggest a likely negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
